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ABSTRACT
Introduction: Standard treatment for patients
with primary immunodeficiency (PID) is
monthly intravenous immunoglobulin
(IVIG), or weekly/biweekly subcutaneous
immunoglobulin (SCIG) infusion. We used
population pharmacokinetic modeling to
predict immunoglobulin G (IgG) exposure
following a broad range of SCIG dosing
regimens for initiation and maintenance
therapy in patients with PID.
Methods: Simulations of SCIG dosing were
performed to predict IgG concentration–time
profiles and exposure metrics [steady-state area
under the IgG concentration–time curve (AUC),
IgG peak concentration (Cmax), and IgG trough
concentration (Cmin) ratios] for various infusion
regimens.
Results: The equivalent of a weekly SCIG
maintenance dose administered one, two,
three, five, or seven times per week, or
biweekly produced overlapping steady-state
concentration–time profiles and similar AUC,
Cmax, and Cmin values [95% confidence interval
(CI) for ratios was 0.98–1.03, 0.95–1.09, and
0.92–1.08, respectively]. Administration every 3
or 4 weeks resulted in higher peaks and lower
troughs; the 95% CI of the AUC, Cmax, and Cmin
ratios was 0.97–1.04, 1.07–1.26, and 0.86–0.95,
respectively. IgG levels[7 g/L were reached
within 1 week using a loading dose regimen in
which the weekly maintenance dose was
administered five times in the first week of
treatment. In patients with very low
endogenous IgG levels, administering 1.5
times the weekly maintenance dose five times
in the first week of treatment resulted in a
similar response.
Conclusions: The same total weekly SCIG dose
can be administered at different intervals, from
daily to biweekly, with minimal impact on
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serum IgG levels. Several SCIG loading regimens
rapidly achieve adequate serum IgG levels in
treatment-naı¨ve patients.
Keywords: Biological therapy; Dosing
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Patients with primary immunodeficiency (PID),
including those with common variable
immunodeficiency (CVID) and X-linked
agammaglobulinemia (XLA), are predisposed to
recurrent and persistent infections [1–7].
Immunoglobulin G (IgG) replacement therapy
provides an effective prophylaxis, and
for 30 years, monthly intravenous
immunoglobulin (IVIG) has been the standard
treatment. However, subcutaneous
immunoglobulin (SCIG) given at weekly or
biweekly (i.e., every 2 weeks) intervals has
become an increasingly popular alternative,
which has been boosted by the development of
increasingly concentrated formulations (as high
as 20%) enabling reduced infusion volumes and
increased infusion rates [8–21].
By comparison with monthly IVIG infusion,
patients receiving a weekly SCIG dose
experience similar protection and infection
rates, but demonstrate increased consistency
in steady-state IgG levels (reduced peak/trough
variation) and suffer fewer systemic adverse
events [9, 15, 16, 22–24]. In addition, SCIG
preparations can be self-administered at home
by most patients. This reduces treatment cost
and increases patient convenience, reflected by
a measured improvement in patient quality of
life [25, 26].
Subcutaneous immunoglobulin regimens
typically divide the total monthly IgG dose
into 4 weekly infusions. However, greater
patient convenience would be achieved by
increasing the flexibility of the dosing regimen
and enabling individualized dosing schedules. A
few clinical trials exploring alternative SCIG
dosing regimens have been published [27–29],
but testing numerous regimens clinically would
be time and cost intensive, and may be
burdensome for patients. A powerful approach
to test a broad range of dosing regimens is
population pharmacokinetic (PK) modeling and
simulation [30–35]. By implementing PK
models based upon existing clinical data, it is
possible to simulate the kinetics of IgG
following modification of variables defining a
dosing regimen.
We recently developed and validated a
population PK model to predict IgG
concentration metrics for SCIG and IVIG
dosing [36]. Model-based simulations
pharmacokinetically supported that a switch
from weekly SCIG to biweekly SCIG infusion at
double the weekly dose maintained equivalent
plasma IgG levels. The biweekly dosing regimen
has recently been approved by both the US Food
and Drug Administration and the European
Medicines Agency for Hizentra (20% SCIG;
CSL Behring AG, Bern, Switzerland) based on
this modeling and simulation [37, 38]. The aim
of this investigation was to use the same model
to make a broader range of predictions to
address the flexibility of SCIG administration.
First, the model was used to predict IgG kinetics
following dosing regimens ranging from daily
to monthly administrations, including the
influence of skipped doses. Second, various
loading regimens were simulated to measure
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the time to steady-state IgG concentrations in
treatment-naı¨ve patients commencing SCIG
therapy.
METHODS
This article does not contain any new studies
with human or animal subjects performed by
the authors.
Pharmacokinetic Model Development
A PK model was developed using IgG
concentration data obtained from four Phase III
trials (Clinicaltrials.gov: NCT00168025,
NCT00419341, NCT00322556, NCT00542997)
in patients with PID treated with either
Privigen (CSL Behring AG, Bern, Switzerland)
IVIG and/or Hizentra SCIG, as previously
described [36]. In brief, a total of 3,837 IgG
concentrations from 151 unique study patients
were used to develop two reference models:
RM1.5, assuming a baseline (endogenous) IgG
concentration of 1.5 g/L (as expected in
predominantly XLA patient populations) and
RM4.0, assuming an endogenous IgG level of 4 g/
L (representative for PID population with mostly
patients with CVID). The PK model is a standard
two-compartment model, with SCIG absorption
modeled as a first-order process (Fig. 1).
Evaluation of the reference models was
performed using sensitivity analyses, visual
predictive checks, and external validation [36].
Simulations
Reference population PK models, RM4.0 and
RM1.5, were used to simulate several
subcutaneous Hizentra dosing regimens for
evaluation of steady-state IgG concentration–
time profiles and IgG exposure metrics. The
same total dose (100 mg/kg/week in a 60-kg
patient with PID) was applied when simulating
different dosing frequency regimens.
Simulations were performed with NONMEM
v7.2, using either S? (SolutionMetrics, Sydney,
NSW, Australia) or R for data management and
graphic creation.
Variable Dose Frequency
A trial consisting of 2,500 patients was
simulated to compare steady-state IgG
concentration–time profiles between a weekly
SCIG administration regimen, with more
frequent (daily, five times a week, three times
a week, and twice a week) and less frequent
(biweekly, every 3 weeks, and every 4 weeks)
dosing regimens. Simulations for more frequent
dosing assumed daily dosing Monday–Sunday;
five times per week (e.g., dosing daily Monday–
Friday); three times a week (e.g., dosing on
Monday, Wednesday, and Friday); and twice a
week infusions (e.g., on Monday and Thursday).
In addition, 300 trials, each with 25 patients,
were simulated to derive steady-state IgG PK
parameters [area under the curve (AUC),
maximum concentration (Cmax) and minimum
concentration (Cmin)] for each regimen. For
each exposure metric, the mean of individual
ratios of weekly SCIG versus an alternative
regimen was calculated for each simulated
trial. The median, 5th, and 95th percentiles of
the within-trial means were subsequently
derived.
Impact of Skipped Doses
Steady-state IgG concentration profiles were
simulated (1 trial consisting of 2,500 patients,
using reference model RM4.0), in which doses
were skipped during daily, weekly and biweekly
dosing regimens. For a daily dosing regimen,
two or three consecutive skipped doses were
simulated, with or without dose replacement.
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For simulations in which skipped doses were
included when dosing was resumed, the
following dose would be three times the daily
dose following two consecutive skipped doses,
or four times the daily dose following three
consecutive skipped doses. A weekly dosing
regimen was simulated in which one, two, or
three consecutive doses were skipped and
replaced when dosing was resumed. For
biweekly dosing, a single skipped dose was
simulated. For both weekly and biweekly
dosing regimens additional simulations were
performed to predict the effect of a double dose
followed by a single skipped dose, without dose
replacement of the skipped dose.
To assess poor compliance, the effect of a
daily dosing regimen, in which one or two
doses were skipped without replacement every
week for an extended period of time, was
simulated.
Loading Dose Regimens
A study consisting of 2,500 patients was
simulated to measure and compare IgG
concentration–time profiles for different SCIG
loading dose strategies in IgG treatment-naı¨ve
patients. Six SCIG loading dose regimens were
explored, as summarized in Table 1, with
100 mg/kg/week considered as a reference
dose. Following the specified loading dose,




of Varied SCIG Dosing Regimens
A broad range of SCIG dosing regimens was
simulated to predict steady-state serum IgG
exposures relative to a weekly SCIG regimen.
While the frequency of dose administration was
varied, the cumulative simulated dose remained
constant (100 mg/kg/week).
Using the RM4.0 model, simulations showed
that higher dosing frequency regimens provided
similar IgG concentration profiles to weekly
dosing, with minimal differences in either
Fig. 1 Schematic diagram of the two-compartment popu-
lation PK model. CL clearance (L/day), F1 bioavailability
of subcutaneous (SC) immunoglobulin, F2 bioavailability
of intravenous (IV) immunoglobulin (=1.00), IgGENDO
endogenous serum IgG concentration (g/L), KA absorption
rate constant of subcutaneous dose (day-1), Q inter-
compartmental clearance (L/day), R1 rate of subcutaneous
dose administration (g/day), R2 rate of intravenous
administration (g/day), V2 volume of distribution of
central compartment (L), V3 volume of distribution of
peripheral compartment (L). Reprinted from Postgraduate
Medicine, 125, Landersdorfer CB, Bexon M, Edelman J,
et al. Pharmacokinetic modeling and simulation of biweekly
subcutaneous immunoglobulin dosing in primary immu-
nodeﬁciency, page 55, Copyright 2013, with permission
from JTE Multimedia, LLC
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median steady-state IgG concentration or the
concentration distribution (Fig. 2). This was
reflected in the exposure metric data, where
median AUC0–7 days ratios for treatment intervals
more frequent than weekly were within 3% of
those for weekly administration, and Cmax ratios
within 5%. The minimum IgG exposure was
consistently greater for the more frequent
dosing regimens, but not by more than 8%.
This indicates that SCIG dosing regimens
administered more frequently than once a
week, in which the same total weekly dose is
administered, would provide equivalent steady-
state IgG exposures.
Table 1 Simulated loading SCIG regimens for treatment-naı¨ve subjects
Regimena Day (Week 1) Day (Week 2)
1 2 3 4 5 6 7 8 9 10 11 12 13 14
100 mg/kg 5 times a week 1WK 100 100 100 100 100
150 mg/kg 5 times a week 1WK 150 150 150 150 150
100 mg/kg 2 times a week 2WK 100 100 100 100
150 mg/kg 2 times a week 2WK 150 150 150 150
100 mg/kg 3 times a week 2WK 100 100 100 100 100 100
100 mg/kg 5 times a week 2WK 100 100 100 100 100 100 100 100 100 100
SCIG subcutaneous immunoglobulin
a All loading dose regimens maintained with 100 mg/kg weekly SCIG from day 15 onwards
Fig. 2 Steady-state IgG concentration–time proﬁles for
various simulated subcutaneous immunoglobulin dosing
regimens, using the RM4.0 reference model. Median IgG
concentrations (black line) with 5th and 95th percentile
(blue shaded area) for weekly dosing, compared with
median concentrations (red line) and 5th to 95th percen-
tiles (red shaded area) of IgG concentration for alternative
dosing regimens. Cmin and Cmax values are also displayed in
tabulated form. AUC area under the concentration–time
curve, IgG immunoglobulin G, Cmin minimum concentra-
tion, Cmax maximum concentration, PK pharmacokinetic,
SC subcutaneous
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With regard to regimens less frequent than
weekly dosing, predicted IgG concentration
profiles were similar to those for weekly and
biweekly dosing, but deviations were more
apparent when dosing was every 3 or 4 weeks
(Fig. 2). The average IgG exposure was
consistent with frequent dosing regimens, in
which median AUC ratios were within 4% of
that for the weekly dose regimen, though Cmax
and Cmin were notably more divergent. While
median Cmin ratios for biweekly dosing were
within 8% of weekly dosing, dosing every 3 or
every 4 weeks was predicted to result in
minimum exposure up to 12 and 14% lower
than weekly dosing, respectively. By contrast,
maximum IgG concentration when dosing
every 4 weeks was up to 26% higher than
experienced when dosing weekly.
This indicates that, while weekly and
biweekly dosings provide comparable IgG
exposure, IgG concentrations following dosing
every 3 or 4 weeks may drop to less than 90% of
steady-state levels toward the end of the dosing
interval. Simulations performed with the RM1.5
model gave similar results (not shown).
On a daily dosing regimen, skipped or missed
doses can be replaced with minimal impact on
plasma IgG levels: simulated steady-state
concentration profiles showed that the
influence of up to three consecutive skipped
doses resulted in only a 4% reduction in average
concentrations relative to consistent daily
dosing (Fig. 3a, b). Exposure recovered within
2 to 3 days when administration was resumed
and the next doses increased to administer the
same total weekly dose (Fig. 3a). When the
skipped doses were not replaced, there was a
small, but long-lasting decrease in steady-state
IgG levels (Fig. 3b). If doses were repeatedly
missed and not replaced, the deficit
accumulated. For example, if a patient on a
daily dosing schedule regularly missed one or
two doses per week over a period of several
months, a new steady-state IgG level was
reached; the average was 9 or 18% below the
original target level, respectively.
On a simulated weekly dosing regimen, one,
two or three skipped doses led to a decrease in
average trough levels by 9, 15, and 19%,
respectively. This recovered rapidly upon
replacement of the skipped dose at the next
infusion (Fig. 3c). A skipped dose on a biweekly
schedule led to an average decrease in trough
level by 13%, which also recovered rapidly after
replacement. In anticipation of a skipped dose,
a double dose can be administered during a
weekly or biweekly regimen. The average peak
concentration after the double dose was
increased by 8% on weekly, and 16% on
biweekly dosing, compared with the peak
concentration achieved with a standard dose.
However, the impact on subsequent trough
levels was small (average 3% decrease on
weekly and 5% on biweekly regimens) (Fig. 3d).
Loading Regimens for Initiating SCIG
Therapy
When SCIG therapy initiation was simulated in
IgG treatment-naı¨ve patients in the absence of a
loading phase, the predicted time to achieve
IgG levels of 7 g/L was 13 weeks when
endogenous IgG was 4 g/L, and in excess of
24 weeks, when endogenous IgG was 1.5 g/L
(Fig. 4a, b). The respective times to achieve 90%
of steady-state IgG levels were 15 weeks and
22 weeks.
In simulations with endogenous IgG level of
4 g/L, the time to 7 g/L and 90% steady state
was reduced to less than 1 week when the
weekly SCIG maintenance dose of 100 mg/kg
was administered five times during the first
week of treatment (100 mg/kg 5 times a week
1WK), or a dose of 150 mg/kg was administered
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five times during the first week of treatment
(150 mg/kg 5 times a week 1WK), before
adopting weekly maintenance dosing (Fig. 4a).
With the 100 mg/kg 5 times a week 1WK
loading phase, there was a transient drop of
IgG below 7 g/L when switching to the
maintenance dose. However, this drop was
relatively minor and sustained levels over
7 g/L were achieved by Week 7.
In simulations with endogenous IgG level of
1.5 g/L, the 150 mg/kg 5 times a week 1WK
loading phase provided IgG levels above 7 g/L
and 90% steady-state concentrations within
1 week, with a small transient drop in IgG
levels when switching to weekly maintenance
dose. By comparison, the 100 mg/kg 5 times a
week 1WK regimen did not achieve IgG levels
above 7 g/L until week 21.
An intensive loading regimen of 100 mg/kg
administered five times a week during the first
2 weeks of treatment (100 mg/kg 5 times a week
2WK) was predicted to rapidly achieve and
Fig. 3 Simulations for skipped doses during daily and
weekly subcutaneous immunoglobulin. Median steady-state
IgG concentrations simulating a daily dosing regimen (black
line) in which either two (blue line) or three (red line)
consecutive doses are skipped, and where there is
(a) compensation or (b) no compensation for skipped
doses upon resumption of daily dosing. c Median steady-
state IgG concentrations for a weekly dosing regimen (black
line) in which either one (green line), two (blue line), or
three (red line) doses are skipped from day 21 and
compensated for upon resuming therapy, or (d) a double
dose administered on day 21 and a dose skipped on day 28,
without compensation. IgG immunoglobulin G
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maintain IgG levels above 7 g/L (Fig. 4b). Less
intensive 2-week loading regimens of either
100 mg/kg administered three times per week
during the first 2 weeks of treatment (100 mg/kg
3 times a week 2WK) or 150 mg/kg administered
two times per week during the first 2 weeks of
treatment (150 mg/kg 2 times a week 2WK)
were able to achieve IgG levels above 7 g/L in
2 weeks in simulations with an endogenous IgG
level of 4.0 g/L (Fig. 4b). A small transient drop
in IgG level, when switching to the
maintenance dose, was recovered by Week 6.
As developed models were applied to a new
patient population (i.e., treatment-naı¨ve
Fig. 4 Simulated IgG concentration–time proﬁles for
various subcutaneous immunoglobulin (SCIG) loading
regimens. Steady-state (gray line) and SCIG without a
loading phase (black line) are shown as comparators for
different loading dose regimen. a 1-week loading phase
using models RM4.0 and RM1.5 and (b) 2-week loading
phase using model RM4.0. c Loading regimen of
5 9 100 mg/kg WK1 using model RM4.0 (black line)
overlaid on observed clinical data (gray circles mean IgG
concentration; gray lines standard error of the mean)
reported by Borte et al. [39]. AUC area under the
concentration–time curve, IgG immunoglobulin G, QW
once a week
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subjects) in this simulation study, it was
important to compare simulated data with
previously published data in such patients. For
this reason, we overlaid the clinical IgG
concentrations following loading of five
consecutive SCIG daily doses of 100 mg/kg
Vivaglobin (CSL Behring GmbH, Marburg,
Germany) in previously untreated patients
obtained by Borte et al. [39], with our
equivalent simulated data (Fig. 4c). The
overlay suggests that the two sets of data are
comparable, both with respect to the initial
loading phase in the first week and the
subsequent maintenance phase.
DISCUSSION
Infused IgG has an elimination half-life of
approximately 36 days [40]. Therefore, any
dosing regimen with a frequency greater than
monthly administration appears feasible from
a PK point of view. While the recommended
dosing for SCIG is weekly or biweekly
administration, more frequent dosing
regimens (up to daily) have been adopted by
some patients [27, 28]. To assess the IgG
kinetics for dosing regimens of higher and
lower frequency than weekly dosing, we used a
previously validated PK model to simulate
events [36]. PK model-based simulations
indicated that so long as the total dose of
IgG remained constant, there is little
difference in IgG exposure metrics when
dosing as frequently as daily and up to
biweekly. These data support the effectiveness
of the varied dosing regimens already used by
some patients.
The clinical advantage of frequent dosing is
that serum IgG concentrations are more stable,
resulting in somewhat higher IgG trough
concentrations and reduced peak-to-trough
variation. Due to the lack of low IgG trough
levels in the days before the next infusion,
patients receiving weekly SCIG therapy do not
report the wear-off effects experienced by those
receiving IVIG toward the end of the 3- or
4-week interval. Simulations presented here
showed that SCIG dosing intervals could be
extended to biweekly with minimal influence
upon serum IgG concentration, whereas
3-weekly and 4-weekly dosing resulted in
divergent Cmax and Cmin values. For this
reason, and in terms of maintaining relative
equivalency to weekly dosing, we recommend
dosing regimens from daily to biweekly (in
which the same weekly total dose is
administered), but would not recommend
dosing intervals from 3-weekly and beyond.
Although this reasoning is somewhat
subjective, a further consideration concerning
the extension of the dosing interval is that
greater subcutaneous injection volumes are
required, which can become uncomfortable.
However, given the variability of IgG half-life
among individuals, a 3-weekly or 4-weekly
regimen maybe suitable for some patients
requiring a rather low dose. Flexibility in the
dosing regimen from daily to biweekly enables
patients to choose a regimen based on
convenience or lifestyle. Possibly this can also
improve compliance.
Clear benefits exist for patients offered
individualized dosing regimens, tailored to
their convenience. Conventional SCIG
administration is by infusion pump.
However, push administration, using a
syringe and butterfly needle, offers a simple
alternative at a lower cost (no requirement
for a pump). This technique is more suited to
frequent administration of lower dose
volumes. Retrospective analyses have shown
that push administration is preferred by
patients as an easier and more convenient
approach [26, 27]. In these studies, patients
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chose to dose on average every 2–3 days
regardless of administration procedure,
showing that even when patients were
administering IgG by pump, they had a
preference for a frequent dosing schedule.
Some patients administering by pump also
reported feeling better when infusing smaller
volumes more frequently, although, this may
be anecdotal [27].
There is also some flexibility within the
dosing regimens as demonstrated by the small
impact of 2–3 skipped doses on IgG levels during
daily dosing, so long as the doses skipped are
compensated for. These data show that if for
whatever reason patients are unable to adhere
strictly to their dosing regimen, it is simple and
practical to compensate. For patients on a weekly
or biweekly dosing regimen, trough IgG levels
also recovered rapidly upon replacement of
skipped doses. However, there is a greater
impact on IgG trough levels when doses are
skipped on these less frequent regimens, with a
risk of IgG levels dropping below a protective
level. It would, therefore, not be recommended
to skip more than a single dose on a weekly
regimen. In addition, the extra volume required
to replace these doses during the following
infusion could be an issue. By contrast, a double
dose before a planned skipped dose had a
minimal impact on the trough IgG levels for
both weekly and biweekly dosing regimens.
Therefore, this would be a feasible option for
patients for whom on certain occasions it may be
inconvenient to maintain their usual dosing
pattern. For example, patients who are traveling
or on vacation may take advantage of this option.
If skipped doses are not compensated when
the regular daily dosing is resumed, it takes up
to 5–6 weeks to return to steady-state levels. For
patients with low IgG levels, or who require
higher IgG levels for protection against
infection, skipped doses should be
compensated for as soon as possible. However,
this practice should be advised for all patients. If
doses are repeatedly skipped and not replaced,
the deficit will accumulate. Within a few
months of consistently missing one or two
doses per week on a daily regimen, predicted
IgG trough concentrations dropped to levels
which may be under-protective. Compliance
with the treatment regimen is, therefore,
essential.
The data generated to determine the
flexibility within dosing regimens were
consistent between the two reference models,
RM4.0 and RM1.5, for all simulated dosing
regimens. These models represent endogenous
IgG concentrations of 4 and 1.5 g/L and are
reflective of the average endogenous IgG
concentrations for predominantly CVID and
XLA patient populations, respectively, thereby
indicating that the flexibility within the dosing
regimens is applicable to both patient
populations.
An initial IVIG loading period before SCIG is
not always practical and can be more
problematic in children and the elderly, where
venous accessibility may be an issue. In
addition, treatment-naı¨ve patients are more
likely to experience adverse events to IVIG
during the first and second infusions [41].
However, in treatment-naı¨ve patients, SCIG
therapy started at a constant weekly dose may
take up to 6 months to achieve steady-state IgG
levels [42]. Obviously, achieving adequate IgG
concentrations as quickly as feasible is desirable
for clinical efficacy. Borte et al. [39] have
described a loading regimen, in which the
weekly dose of 100 mg/kg was delivered five
times during the first week, before adjusting the
patient to a weekly dosing regimen. Nearly, all
patients achieved IgG concentrations C5 g/L by
day 12. An additional advantage of this loading
regimen is that the loading phase can be used
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for training the patient in self-administration,
the five loading doses being administered under
the supervision of a nurse.
IgG concentration above 7 g/L (representing
the lower limit of IgG in healthy adults [43, 44])
is considered to provide adequate protection
from infection, and was recommended by a
Canadian consensus guideline as the minimum
IgG trough level to achieve in most patients [45,
46], although it is recognized that some patients
may need a higher IgG level [47]. Our
simulation data predicted that, in the absence
of a loading dose, IgG concentrations of 7 g/L
for SCIG dosing would only be attained after a
period of 13 weeks if endogenous IgG was 4 g/L,
or after more than 24 weeks if endogenous IgG
was as low as 1.5 g/L. Three loading regimens
were identified, which ensured that IgG
concentrations were rapidly raised to
protective quasi-steady-state levels. The first of
these regimens was the delivery of the weekly
dose of 100 mg/kg for 5 consecutive days during
the first week of treatment, as also described by
Borte et al. [39]. RM4.0 model simulations were
highly comparable to these clinical data, and
predicted that this would raise IgG
concentrations above 7 g/L within 1 week of
treatment initiation and thus provide rapid
protection against infection for newly
diagnosed patients. However, in the RM1.5
model, these levels were reached only after
21 weeks. This loading regimen may, therefore,
be suitable for patients with higher endogenous
(pre-therapy) IgG levels, such as patients with
CVID, but not in patients with more severe
disease or lower endogenous IgG, such as XLA.
In such patients, a loading regimen of 150 mg/
kg IgG administered five times during the first
week of treatment, or 100 mg/kg administered
five times during each of the first 2 weeks of
treatment achieved IgG levels above 7 g/L
within 2 weeks. These loading regimens would
obviously also work for endogenous IgG levels
of 4 g/L.
In addition, less intensive loading schedules
of either 100 mg/kg three times a week or
150 mg/kg two times a week, administered
over a 2-week period were able to raise IgG
levels above 7 g/L within 2 weeks, when
endogenous IgG was 4.0 g/L. These loading
regimens might serve as alternatives for
patients and physicians who prefer to use a
less condensed dosing schedule. When
determining clinical recommendations for
loading dose regimens, non-PK factors related
to clinical feasibility should be considered. This
includes reaching IgG levels that would
adequately protect the majority of the patient
population, while considering patients’
convenience with respect to the required
frequency of infusions, infusion volume,
number of injection sites, and potential dose
compliance. With this in mind, the loading
dose of five consecutive infusions of 100 mg/kg
during the first week, followed by the regular
weekly dose of 100 mg/kg might be the most
appropriate for the majority of patients.
For patients with low endogenous IgG level,
a loading dose of one and a half times the
weekly dose of 100 mg/kg administered five
times during the first week of treatment may be
considered more appropriate. Similar IgG
concentration levels obtained by this more
intense loading strategy may also be achieved
by loading 100 mg/kg for five consecutive
infusions during each of the first 2 weeks of
SCIG therapy. However, this approach does not
appear to offer any clinically important
advantage, may place a higher burden upon
patients, and is a more costly alternative. Less
intense loading schedules of 150 mg/kg two
times per week or 100 mg/kg three times per
week for two consecutive weeks may still be
appropriate for some patients with non-severe
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initial condition, relatively high endogenous
IgG levels, or those who would like to avoid
daily infusions for five consecutive days.
For the above reasons, depending upon the
baseline IgG level, an SCIG loading regimen of
100 or 150 mg/kg for five consecutive days in
the first week of treatment is predicted to
quickly elevate the patient’s serum IgG levels
to protective quasi-steady-state levels without
the need for an initial IVIG loading dose. After
the loading period, the SCIG dose can be
adjusted on an individual basis dependent
upon IgG levels and clinical response.
All simulations presented here were
performed with respect to achieving levels
around 7 g/L. While this level is probably
protective in many patients, it is a somewhat
hypothetical value. In practice it is important to
identify the individual’s protective ‘biologic IgG
level’, above which the patient remains
essentially infection free, with the aim of
achieving and maintaining this IgG
concentration [47]. Dose levels have to be
adapted accordingly. For a CVID patient
population, we assumed an endogenous IgG
concentration of 4 g/L; we did not take into
account the functional status of this IgG, which
can be compromised [7]. These patients may
require a higher ‘biologic IgG level’. In addition,
the efficacy of Ig therapy, i.e., the dose required
to achieve a given increase in IgG trough levels,
varies from patient to patient, making further
dose adjustment necessary [48].
If, in a treatment-naı¨ve patient, it can be
anticipated that the target IgG trough level is
higher than 7 g/L and, as a consequence, the
maintenance dose is higher than 100 mg/kg/
week, a loading regimen of the planned
maintenance dose administered on five
consecutive days is appropriate to bring the
serum IgG concentration to the target ‘biologic
IgG level’ within one week. If, in addition, this
patient has a low endogenous IgG, one and a
half times the planned maintenance dose
administered 5 days in Week 1 may be required.
In considering the dosing regimens assessed
in our work, particularly that for loading doses,
a limitation to the modeling needs to be noted.
The PK model on which the presented
simulations were based was derived using data
obtained in clinical trial subjects, all of whom
had received IgG therapies prior to their study
participation. As there was no PK data from IgG
treatment-naı¨ve subjects, methodological
assumptions had to be made about the status
of endogenous IgG levels. We chose to fix
endogenous IgG in the model to a value
within a range of 1.5–4.0 g/L. Consequently,
confirmation of our assessments of various
SCIG loading dose possibilities is warranted.
However, the endogenous IgG level limitation
is of much lesser importance for our
assessments of various SCIG maintenance
regimens, whereby a fixed endogenous level
was held constant between comparative dosing
regimens.
CONCLUSION
PK modeling predicts that similar IgG
concentrations are achieved with a dosing
frequency of every 2 weeks or less, so long as
the cumulative total dose remains consistent.
IgG levels of 7 g/L are achievable in treatment-
naı¨ve patients with several SCIG loading
regimens during the first 1–2 weeks of SCIG
treatment and would provide greater
convenience for patients with PID.
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